Boryung announced on the 21st that it has signed an asset transfer contract with Eli Lilly for the schizophrenia treatment "Zyprexa (Olanzapine)." Through this contract, Boryung will take over all rights from Eli Lilly, including domestic copyrights and permits for Zyprexa.

Zyprexa is the world's most prescribed treatment for schizophrenia since its launch in 1996. It is a drug used for schizophrenia and bipolar disorder and controls the imbalance of Dopamine in the brain. According to IQVIA, a pharmaceutical market research firm, Zyprexa generated 14 billion won in sales in Korea last year. It occupies about 50% of the domestic Olanzapine market.

Boryung plans to further strengthen its